Iron Infusion and Induced Hypophosphatemia: The Role of Fibroblast Growth Factor‐23

The mechanism of action of fibroblast growth factor‐23 (FGF23) is becoming increasingly clearer as a result of studies that have defined its structure and pleiotropic effects. Furthermore, data are emerging on the effects exerted on this hormone by iron administration. Ten main iron formulations are recognized (with clear differences in composition and possible reactions of intolerance and anaphylaxis), which are indicated for iron deficiency anemia, including nephropathic subjects, as suggested by medical guidelines. With some types of iron formulation (especially iron carboxymaltose) a particular side effect has been observed: hypophosphatemia, mediated by FGF23. This review aims to draw attention to this correlation and the contradiction represented by the presence of both positive and negative modulation by FGF23, with the effects induced by its increase even after long‐term treatment with iron formulation. However, more evidence is needed to understand the reasons for this differential stimulation.

• Publication year

  2020

• Venue

  Therapeutic apheresis and dialysis

• Publication date

  2020-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/1744-9987.13435PMID 31483921
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Estimating the distribution of a novel clinical biomarker (FGF-23) in the US population using findings from a regional research registry

  2019cited by this paper
• Incremental dialysis in ESRD: systematic review and meta-analysis

  2019cited by this paper
• Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration

  2018cited by this paper
• Oral Versus Intravenous Iron Supplementation for the Treatment of Iron Deficiency Anemia in Patients on Maintenance Hemodialysis-Effect on Fibroblast Growth Factor-23 Metabolism.

  2018cited by this paper
• X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.

  2018cited by this paper
• Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency

  2018cited by this paper
• Phosphate homeostasis disorders.

  2018cited by this paper
• Effect of Increased Convection Volume by Mid-Dilution Hemodiafiltration on the Subclinical Chronic Inflammation in Maintenance Hemodialysis Patients

  2018cited by this paper
• Fibroblast growth factor 23 is induced by an activated renin–angiotensin–aldosterone system in cardiac myocytes and promotes the pro-fibrotic crosstalk between cardiac myocytes and fibroblasts

  2018cited by this paper
• Admission serum phosphate levels predict hospital mortality

  2018cited by this paper
• Associations Between Intravenous Iron, Inflammation and FGF23 in Non-Dialysis Patients with Chronic Kidney Disease Stages 3-5

  2018cited by this paper
• High fibroblast growth factor 23 levels are associated with decreased ferritin levels and increased intravenous iron doses in hemodialysis patients

  2017cited by this paper
• Management of anemia in inflammatory bowel disease: a challenge in everyday clinical practice

  2017cited by this paper
• Cardiovascular consequences of hypophosphatemia.

  2017cited by this paper
• Iron-induced hypophosphatemia: an emerging complication

  2017cited by this paper
• [Correlations of FGF23 and Klotho with cardiovascular injury in chronic kidney disease patients].

  2017cited by this paper
• Counter‐regulatory paracrine actions of FGF‐23 and 1,25(OH)2D in macrophages

  2016cited by this paper
• FGF23 signaling impairs neutrophil recruitment and host defense during CKD.

  2016cited by this paper
• Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial

  2016cited by this paper
• Inflammation regulates fibroblast growth factor 23 production

  2016cited by this paper
• Fibroblast growth factor 23, iron and inflammation – are they related in early stages of chronic kidney disease?

  2016cited by this paper
• Fibroblast Growth Factor-23—A Potential Uremic Toxin

  2016cited by this paper
• Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide

  2016cited by this paper
• Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial.

  2015cited by this paper
• Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy.

  2015cited by this paper
• Fibroblast growth factor is associated to left ventricular mass index, anemia and low values of transferrin saturation.

  2015cited by this paper
• [Clinical experience with ferric carboxymaltose in non-dialysis chronic kidney disease].

  2015cited by this paper
• Serum β-Crosslaps as Predictor of Long-term Parathyroid Hormone Levels in Hemodialysis Patients

  2015cited by this paper
• Experimental Myocardial Infarction Upregulates Circulating Fibroblast Growth Factor‐23

  2015cited by this paper
• The PTH-Vitamin D-FGF23 axis

  2015cited by this paper
• Mineral (Mal)Adaptation to Kidney Disease--Young Investigator Award Address: American Society of Nephrology Kidney Week 2014.

  2015cited by this paper
• Plasma fibroblast growth factor 23 concentration and iron status. Does the relationship exist in the elderly population?

  2015cited by this paper
• Sevalamer Hydrochloride, Sevelamer Carbonate and Lanthanum Carbonate: In Vitro and In Vivo Effects on Gastric Environment

  2015cited by this paper
• Suppression of iron-regulatory hepcidin by vitamin D.

  2014cited by this paper
• The future of phosphate binders: a perspective on novel therapeutics

  2014cited by this paper
• Tumour Markers and Kidney Function: A Systematic Review

  2014cited by this paper
• Iron and Obesity Status-Associated Insulin Resistance Influence Circulating Fibroblast-Growth Factor-23 Concentrations

  2013cited by this paper
• The effects of iron on FGF23-mediated Ca–P metabolism in CKD patients

  2013cited by this paper
• Fibroblast growth factor 23 is not associated with and does not induce arterial calcification

  2013cited by this paper
• FGF23 regulates renal sodium handling and blood pressure

  2012cited by this paper
• Fibroblast growth factor 23: state of the field and future directions.

  2012influential reference
• Regulation and function of the FGF23/klotho endocrine pathways.

  2012cited by this paper
• Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism

  2012cited by this paper
• Low Molecular Weight Iron Dextran Increases Fibroblast Growth Factor‐23 Concentration, Together With Parathyroid Hormone Decrease in Hemodialyzed Patients

  2012cited by this paper
• Fibroblast growth factor 23-related osteomalacia caused by the prolonged administration of saccharated ferric oxide.

  2012cited by this paper
• Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans.

  2011cited by this paper
• Parathyroid Hormone and Mobilization of Circulating Bone Marrow-Derived Cells in Uremic Patients

  2011cited by this paper
• Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice

  2011cited by this paper
• FGF23 induces left ventricular hypertrophy.

  2011cited by this paper
• Progression of coronary artery calcification and cardiac events in patients with chronic renal disease not receiving dialysis

  2011cited by this paper
• Effect of Intravenous Saccharated Ferric Oxide on Serum FGF23 and Mineral Metabolism in Hemodialysis Patients

  2011cited by this paper
• Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23.

  2010cited by this paper
• Neutrophil gelatinase‐associated lipocalin levels in chronic haemodialysis patients

  2010cited by this paper
• Acute cardiovascular complications of hemodialysis.

  2010cited by this paper
• Parathyroid Hormone Variability Parameters for Identifying High Turnover Osteodystrophy Disease in Hemodialysis Patients: An Observational Retrospective Cohort Study

  2010cited by this paper
• Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia.

  2009cited by this paper
• The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays

  2007cited by this paper
• Regulation of Fibroblast Growth Factor-23 Signaling by Klotho*

  2006cited by this paper
• FGF‐23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis

  2003cited by this paper
• Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23

  2000cited by this paper
• Hypophosphatemia induced by intravenous administration of saccharated iron oxide

  1983cited by this paper
• [Rickets following bone tumor].

  1959cited by this paper

• The Significance of Hypophosphatemia in Deciding on an Optimal Clinical Choice of Parenteral Iron Therapy in Patients with Chronic Inflammatory Bowel Disease in Slovenia: An Umbrella Review and Economic Evaluation

  2026cites this paper
• Conventional and complementary alternative medicine therapies for renal anemia: a literature review

  2025cites this paper
• [Metformin-induced lactic acidosis, severe hypophosphatemia and severe hypocalcemia: A diagnostic and therapeutic challenge].

  2025cites this paper
• Gendered Experiences of Intravenous Iron Infusion Reactions: A Patient Perspective

  2025cites this paper
• Danger of co-administration ferric carboxymaltose and denosumab: hypophosphatemia

  2025influential citation
• Coronary Artery Disease in Patients Undergoing Hemodialysis: A Problem that Sounds the Alarm

  2024cites this paper
• Concurrent Denosumab and Parenteral Iron Therapy Precipitating Severe Hypocalcemia and Hypophosphatemia

  2024cites this paper
• Intravenous ferric carboxymaltose is associated with lowering of plasma phosphate levels in patients with gastric bypass surgery: a retrospective case series.

  2024cites this paper
• Osteomalacia: A Challenging Diagnosis Adverse Event Associated with Intravenous Ferric Carboxymaltose—A Case Report

  2024cites this paper
• Severe Hypophosphatemia Occurring After Repeated Exposure to a Parenteral Iron Formulation

  2022cites this paper
• Mineral Bone Disorders in Kidney Disease Patients: The Ever-Current Topic

  2022cites this paper
• Hypophosphatemia in a patient with an eating disorder

  2022cites this paper
• British Intestinal Failure Alliance (BIFA) guidance - haematological and biochemical monitoring of adult patients receiving home parenteral nutrition

  2021cites this paper
• Refractory hypophosphatemia following ferric carboxymaltose administration

  2021cites this paper
• Comparative Risk of Hypophosphatemia Following the Administration of Intravenous Iron Formulations: A Network Meta-Analysis.

  2020cites this paper
• Klotho, Aging, and the Failing Kidney

  2020cites this paper